Price
No data yet.
Social Signal Score
Analyst Ratings
5 analystsRevenue
$1.10MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jonathan C. Javitt
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 29
- Beta
- 2.19
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- -13.34
Financials
Revenue
$1.10M+355.0%Net Income
$-16.52MEBITDA
$-16.21MFree Cash Flow
$-9.77MEPS (diluted)
$-0.44Shares Outstanding (diluted)
37.65M+1893.1%Operating Expenses
$6.86MCash & Debt
$26.69MReturn of Capital
$0.00Revenue by Segment (annual)
$854.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.23M | $-28.62M | $-1.34 |
| 2024 | $0.00 | $-25.13M | $-2.39 |
| 2023 | $0.00 | $-30.15M | $-3.98 |
| 2022 | $0.00 | $-39.75M | $-0.60 |
| 2021 | $0.00 | $-93.06M | $-7.44 |
| 2020 | $0.00 | $-51.78M | $-1.51 |
| 2019 | $0.00 | $408.4K | $0.80 |
| 2018 | $0.00 | $66.1K | $0.07 |
| 2017 | $0.00 | $-105.0K | $-0.12 |
Valuation
NRXPhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-64.29%Social Signal Score
Mentions (10)
- Newsglobenewswire.com·6d ago·Neutral
NRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant Depression DARPA states that the program, if successful, will fundamentally change the Standard of Care for Treatment Resistant Depression. The Military has recognized that current treatments for depression are not deployable in operational military settings.
View source ↗ - Newsglobenewswire.com·20d ago·Negative
NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine WILMINGTON, Del., Sept. 15, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", "NRx" or the "Company"), a clinical-stage biopharmaceutical company, today announced that it has received a written communication from the Director of Regulatory Operations of the FDA Office of Generic Drugs advising the Company that…
View source ↗ - Newsseekingalpha.com·21d ago·Positive
NRx Pharmaceuticals: Promising Ketamine Opportunity In Psychiatry KETAFREE could turn NRXP's ketamine opportunity into a commercial business, provided FDA approval leads to a successful launch. NRXP's HOPE gives them clinical infrastructure, even though it still has a relatively small revenue base. That's why their bull case ultimately depends on successfully commercializing KETAFREE in the future.
View source ↗ - Newsglobenewswire.com·22d ago·Negative
GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS) Invention is based on the discovery that ALS may be caused by reactivation of Human Endogenous Retrovirus K (HERV K) Envelope protein (K Env), already coded in the “dark genome” of all people. K Env is found in the spinal fluid of more than 75% of people with ALS and has been shown to produce the neurodegenerative findings of ALS in experi…
View source ↗ - Newsglobenewswire.com·25d ago·Negative
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System WILMINGTON, Del., Sept. 11, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", "NRx" or the "Company"), a clinical-stage biopharmaceutical company, today announced that its subsidiary, HOPE Therapeutics, Inc. ("HOPE"), will be the first Interventional Psychiatry to deploy Zeta Surgical's newly FDA-cleared Zeta TMS …
View source ↗ - Newsglobenewswire.com·28d ago·Neutral
NRx Pharmaceuticals to Participate in Upcoming Investor Conferences WILMINGTON, Del., Sept. 08, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced that the management team will participate in three upcoming investor conferences in September 2026.
View source ↗ - Newsseekingalpha.com·48d ago·Positive
NRx Pharmaceuticals, Inc. (NRXP) Q2 2026 Earnings Call Transcript NRx Pharmaceuticals, Inc. (NRXP) Q2 2026 Earnings Call Transcript
View source ↗ - Newsglobenewswire.com·50d ago·Positive
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET Key recent and second quarter highlights include: Completed first-cycle FDA review of the Company's ANDA for preservative-free ketamine with no drug-related major deficiencies. The sole remaining item, a manufacturer's attestation on the vial, has been submitted to FDA.
View source ↗ - Newsseekingalpha.com·56d ago·Positive
NRx Pharmaceuticals, Inc. (NRXP) Discusses FDA First Cycle Review Outcome and Commercialization Plans for Preservative Free Ketamine Transcript NRx Pharmaceuticals, Inc. (NRXP) Discusses FDA First Cycle Review Outcome and Commercialization Plans for Preservative Free Ketamine Transcript
View source ↗ - Newsmarketbeat.com·57d ago·Negative
NRx Pharmaceuticals Nears FDA Decision on Preservative-Free Ketamine After Review Clears Hurdles NRx Pharmaceuticals NASDAQ: NRXP said it has completed the first-cycle U.S. Food and Drug Administration review of its abbreviated new drug application, or ANDA, for preservative-free ketamine, with one remaining issue related to the product's vial connector.
View source ↗
Earnings
Fri, Nov 13(in 5 weeks)
Consensus estimate $-0.26 per share
Typical surprise -145.5% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 17$-0.44 vs $-0.11miss
- Fri, May 15$-0.04 vs $-0.05beat
- Mon, Mar 23$0.19 vs $-0.09beat
- Mon, Nov 17$-0.27 vs $-0.11miss
- Mon, Aug 18$-0.98 vs $-0.15miss
- Thu, May 15$-0.34 vs $-0.30miss
Estimates and results for NRXP via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by NRXP officers and directors.
- Bought
- $6.7m
- Sold
- $2.4m
19 trades
10 trades
- Javitt Jonathan Cboughtdirector, 10 percent owner, officer: Chairman and Chief Scientist·40,000 @ $1.17·$47k·Dec 17, 2024·filing
- Gorovitz Aaronbought
- Hurvitz Chaimbought
- Javitt Jonathan Cbought
- Javitt Jonathan Cbought
- Willard Stephen Hbought
- Van Voorhees Sethbought
- Javitt Jonathan Csold
71 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in NRXP.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.